Requires health insurance coverage for early-stage kidney disease screening without cost sharing.
Summary
S4243 would require a broad range of New Jersey health coverage arrangements to pay for early-stage kidney disease screening when a physician determines the screening is medically necessary, and it would prohibit deductibles, copayments, coinsurance, or other cost-sharing for that screening. The mandate applies to hospital, medical, and health service corporation contracts; individual, group, and small employer health insurance policies and health benefits plans; HMO enrollee agreements; and the State Health Benefits Program and School Employees’ Health Benefits Program, subject to federal law for high-deductible and catastrophic plans.
The bill defines early-stage kidney disease screening as either an estimated glomerular filtration rate blood test or a urine albumin-creatinine ratio test. It also creates a presumption that the screening is medically necessary when a physician determines the covered person meets clinical guidelines established by the National Kidney Foundation, or a comparable organization. The bill would take effect on the first day of the fourth month after enactment and apply to policies and contracts delivered, issued, executed, or renewed on or after that date.
Impact
The bill would amend multiple insurance and health-benefit statutes in New Jersey by adding a new coverage mandate across both private and public health plans. It would require insurers, HMOs, and state-administered health benefit programs to cover specified kidney disease screening services without cost sharing, while preserving limited federal-law exceptions for high-deductible health plans, health savings accounts, and medical savings accounts. The practical effect would be to expand preventive and diagnostic access for people at risk of chronic kidney disease and shift the cost of those screenings from patients to carriers and public benefit programs.
Sentiment
The bill text and statement reflect a generally supportive, public-health-oriented rationale, emphasizing rising chronic kidney disease admissions and the value of early detection. No committee transcripts or recorded votes were provided, so there is no direct evidence of opposition or formal debate in the supplied materials. Based on the introduced language, the measure appears framed as a preventive care expansion with an emphasis on affordability and medically necessary screening.
Contention
The main policy issue embedded in the bill is the insurance mandate itself, particularly the requirement that coverage be provided without any cost sharing. Another potential point of contention is the bill’s interaction with federal rules for high-deductible health plans and tax-advantaged accounts, since the mandate must operate only to the extent permitted by federal law. The bill also relies on physician judgment and National Kidney Foundation clinical guidelines to establish medical necessity, which could raise questions about scope, utilization, and insurer administration, though no specific opposition is documented in the materials provided.